Pharma channel feed

Phar­ma rep­u­ta­tion slips among pa­tient ad­vo­ca­cy groups, ac­cord­ing to an­nu­al sur­vey

Last year
Marketing

Sanofi and Re­gen­eron de­but next gen­er­a­tion in Dupix­en­t's asth­ma cam­paign

Last year
Marketing

FDA ap­proves X4 Phar­ma­ceu­ti­cal­s' pill for ul­tra-rare im­mun­od­e­fi­cien­cy dis­ease

Last year
FDA+

Bris­tol My­ers buys in­to Reper­toire's au­toim­mune vac­cines, giv­ing new life to Flag­ship start­up

Last year
Startups
Deals

CHMP rec­om­mends eight new drug ap­provals, six la­bel ex­pan­sions

Last year
FDA+

FDA green­lights la­bel up­date to Gilead­'s Bik­tarvy to in­clude more da­ta in preg­nant peo­ple

Last year
FDA+

Sanders press­es phar­ma lead­ers to change stance on Pan­dem­ic Ac­cord pro­pos­als

Last year
FDA+

Ipsen match­es rare dis­ease and Tik­Tok in­flu­encers to cre­ate con­nec­tions

Last year
Marketing

Bris­tol My­ers to shut­ter Bay Area cell ther­a­py R&D fa­cil­i­ty as it elim­i­nates jobs and costs

Last year
Cell/Gene Tx

Ab­b­Vie beats first-quar­ter ex­pec­ta­tions, but Hu­mi­ra guid­ance leaves an­a­lysts con­fused

Last year

Cigna’s Ever­north just made a move to boost Hu­mi­ra biosim­i­lar use

Last year
Health Tech

Up­dat­ed: FDA ap­proves Pfiz­er’s he­mo­phil­ia B gene ther­a­py, with $3.5M price tag

Last year
Cell/Gene Tx
FDA+

Gilead leans on CymaBay liv­er drug, Trodelvy read­outs and long-ac­tive PrEP yet to come this year

Last year
R&D

In rare move, Colom­bia is­sues com­pul­so­ry li­cense for HIV med­i­cine in ef­fort to ex­pand ac­cess

Last year
FDA+

Es­teve to ac­quire Per­rigo's rare dis­ease phar­ma busi­ness for up to $295M

Last year
Deals

GSK ac­cus­es Pfiz­er and BioN­Tech of mR­NA patent in­fringe­ment

Last year
Law

As­traZeneca on emerg­ing mar­kets, GLP-1 plans and why it’s se­lec­tive about vac­cines

Last year

Sage fo­cus­es on suc­cess­ful launch of post­par­tum de­pres­sion drug

Last year
Marketing

An­oth­er quar­ter, an­oth­er Keytru­da win for Mer­ck

Last year
R&D

Bris­tol My­ers out­lines ‘about 12’ pipeline cuts as it ex­e­cutes ma­jor cut­backs

Last year

Astel­las cuts a bis­pe­cif­ic in can­cer and a mi­to­chon­dria-fo­cused as­set from Mi­to­bridge deal

Last year
R&D

As­traZeneca’s Pas­cal So­ri­ot says new rise in pay is ‘re­al­ly about’ po­ten­tial suc­ces­sor

Last year
People

Up­dat­ed: Bris­tol My­ers plans $1.5B in cost cuts, in­clud­ing 2,200 jobs, as CEO promis­es more ‘ag­ile’ com­pa­ny

Last year

Bio­Mar­in's Roc­ta­vian strug­gles con­tin­ue. Is a di­vest­ment in the fu­ture?

Last year
Cell/Gene Tx
First page Previous page 56575859606162 Next page Last page
A service from the Financial Times